Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus | Zendy

Barry Rockx | Zendy; Eric Donaldson | Zendy; Matthew B. Frieman | Zendy; Timothy P. Sheahan | Zendy; Davide Corti | Zendy; Antonio Lanzavecchia | Zendy; Ralph S. Baric | Zendy

Open Access

Escape from Human Monoclonal Antibody Neutralization Affects In Vitro and In Vivo Fitness of Severe Acute Respiratory Syndrome Coronavirus

Author(s) -

Barry Rockx,

Eric Donaldson,

Matthew B. Frieman,

Timothy P. Sheahan,

Davide Corti,

Antonio Lanzavecchia,

Ralph S. Baric

Publication year - 2010

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/651022

Subject(s) - neutralization , monoclonal antibody , virology , epitope , glycoprotein , biology , antibody , coronavirus , neutralizing antibody , viral replication , in vivo , virus , immunology , medicine , microbiology and biotechnology , covid-19 , genetics , disease , infectious disease (medical specialty) , pathology

Severe acute respiratory syndrome (SARS) emerged as a human disease in 2002. Detailed phylogenetic analysis and epidemiologic studies have suggested that the SARS coronavirus (SARS-CoV) originated from animals. The spike (S) glycoprotein has been identified as a major target of protective immunity and contains 3 regions that are targeted by neutralizing antibodies in the S1 and S2 domains. We previously characterized a panel of neutralizing human monoclonal antibodies (MAbs), but the majority of epitopes recognized by the MAbs remain unknown.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research